ANIX - CIK 0000715446
The table below shows Anixa Biosciences Inc's balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.24M | $1.27M | $915.00K | $12.36M | $6.42M | $3.49M |
| Short-term investments | $13.93M | $18.65M | $22.93M | $17.33M | $2.64M | $2.35M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $15.89M |
| $21.36M |
| $25.36M |
| $30.20M |
| $9.37M |
| $6.09M |
| Property, plant & equipment | - | - | - | - | $200.57K | $200.57K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $16.08M | $21.59M | $25.52M | $30.41M | $9.45M | $6.29M |
| Accounts payable | $165.00K | $525.00K | $206.00K | $265.00K | $232.37K | $585.82K |
| Total current liabilities | $1.97M | $2.50M | $2.03M | $2.04M | $1.19M | $1.48M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $2.13M | $2.70M | $2.15M | $2.21M | - | - |
| Retained earnings | -$251.68M | -$240.75M | -$228.20M | -$218.38M | -$191.84M | -$181.82M |
| Total equity | $15.16M | $20.00M | $24.34M | $29.05M | $8.76M | $5.24M |